Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from NeOnc Technologies Holdings, Inc. ( (NTHI) ) is now available.
NeOnc Technologies Holdings, Inc. announced the impending closure of a $50 million strategic partnership with Quazar Investment, following regulatory approvals from the UAE, expected by October 23, 2025. This partnership, involving NeOnc’s subsidiary NuroCure, aims to accelerate clinical trials and infrastructure development in the MENA region, leveraging the UAE’s advanced clinical trial infrastructure, and is expected to significantly advance NeOnc’s therapeutic pipeline.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics. The company aims to overcome the blood-brain barrier with its NEO drug development platform, which includes novel drug candidates and delivery methods. NeOnc’s NEO100 and NEO212 therapeutics are in Phase II clinical trials, advancing under FDA Fast-Track and IND status, with patent protections extending to 2038.
Average Trading Volume: 164,285
Technical Sentiment Signal: Strong Buy
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.